IONS earnings call for the period ending June 30, 2019.
News & Analysis: Ionis Pharmaceuticals
Royalties are nice, but licensing, milestone, and option payments are getting it done for this biotech.
It can be tough to pick winners in the world of pharmaceutical development, but Alexion, Regeneron, and Ionis offer investors good chances of strong returns.
A large licensing payment from one of the biotech's partners drives revenue growth.
IONS earnings call for the period ending March 31, 2019.
Information from competitors and a collaborator sent the high-flying biotech lower.
Sometimes the best future returns come from companies that have already shown themselves to be successful.
The biotech turned an operating profit in the fourth quarter thanks to revenue from partners.
IONS earnings call for the period ending December 31, 2018.
Fourth-quarter earnings exceed expectations.